Clinical Trial

Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
DILI is an underdiagnosed and under appreciated causal or contributing factor to liver injury. DILI can mimics features of the entire spectrum of acute and chronic liver disease. Asia-Pacifc region is characterized by two unique features; the high prevalence of tuberculosis (TB) in the population and the ubiquitous use of traditional and complimentary medicines.Current definition of Hy's law presents significant difficulties when dealing with patients with preexisting CLD in clinical trials. Hallmark of the hepatic manifestation in these patients is hyperbilirubinemia and coagulopathy rather than ALT elevation.
Trial Details
NCT Number NCT06797011
Lead Sponsor Institute of Liver and Biliary Sciences, India
Conditions Drug Induced Liver Injury, Chronic Liver Disease
Enrollment 96 participants
Start Date 2025-01-25
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-28